



@article {2366,
	title = {Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate},
	journal = {Journal of Plastic, Reconstructive and Aesthetic SurgeryJ. Plast. Reconstr. Aesthetic Surg.},
	volume = {61},
	year = {2008},
	note = {Cited By (since 1996): 3Export Date: 21 November 2012Source: Scopusdoi: 10.1016/j.bjps.2006.06.016PubMed ID: 18068658Language of Original Document: EnglishCorrespondence Address: Maur{\'\i}cio, A.C.; Centro de Estudos de Ci{\^e}ncia Animal (CECA), Instituto de Ci{\^e}ncias, Tecnologias Agr{\'a}rias e Agro-Alimentares (ICETA), Campus Agrario Vairao, Rua Padre Armando Quintas, 4485-661 Vair{\~a}o, Portugal; email: ana.colette@mail.icav.up.ptChemicals/CAS: amoxicillin, 26787-78-0, 34642-77-8, 61336-70-7; cyclophosphamide, 50-18-0; cyclosporin, 79217-60-0; dexamethasone, 50-02-2; erythropoietin, 11096-26-7; thalidomide, 50-35-1; zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7; Bone Density Conservation Agents; Diphosphonates; Imidazoles; zoledronic acid, 118072-93-8References: Mundy, G.R., Bertoline, D.R., Bone destruction and hypercalcemia in plasma cell myeloma (1986) Semin Oncol, 13 (3), pp. 291-299;Belch, A.R., Bergsagel, D.E., Wilson, K., Effect of daily etidronate on the osteolysis of multiple myeloma (1991) J Clin Oncol, 9 (8), pp. 1397-1402; 
Kyle, R.A., Jowsey, J., Kelly, P.J., Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo (1975) N Engl J Med, 293 (26), pp. 1334-1338; 
Kyle, R.A., Multiple myeloma: review of 869 cases (1975) Mayo Clin Proc, 50 (1), pp. 29-40; 
Roodman, G.D., Pathogenesis of myeloma bone disease (2004) Blood Cells Mol Dis, 32 (2), pp. 290-292; 
Berenson, J.R., Myeloma bone disease (2005) Best Pract Res Clin Haematol, 18 (4), pp. 653-672; 
Ruggerio, S.L., Mekrotra, B., Rosenberg, T.J., Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases (2004) J Oral Maxillofac Surg, 62, pp. 527-534; 
Rodan, G.A., Fleisch, H.A., Bisphosphonates: mechanism of action (1996) J Clin Invest, 97 (12), pp. 2692-2696; 
Coleman, R.E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies (2001) Cancer Treat Rev, 27 (3), pp. 165-176; 
Sietsema, W.K., Ebetino, F.H., Salvagno, A.M., Antiresorptive dose-response relationship across three generations of bisphosphonates (1989) Drugs Exp Clin Res, 15 (9), pp. 389-396; 
Schenk, R., Eggli, P., Fleisch, H., Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat (1986) Calcif Tissue Int, 38, pp. 342-349; 
Jung, A., Bisaz, S., Fleisch, H., The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals (1973) Calcif Tissue Res, 11 (4), pp. 269-280; 
Coukell, A.J., Markham, A., Pamidronate. A review of its use in the management of osteolytic bone metastases, tumor-induced~hypercalcaemia and Paget{\textquoteright}s disease of bone (1998) Drugs Aging, 12 (2), pp. 149-168; 
Hughes, D.E., MacDonald, B.R., Russel, R.G.G., Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow (1989) J Clin Invest, 83 (6), pp. 1930-1935; 
Hughes, D.E., Wright, K.R., Uy, H.L., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo (1995) J Bone Miner Res, 10 (10), pp. 1478-1487; 
Murakami, H., Takahashi, N., Sasaki, T., A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders (1995) Bone, 17 (2), pp. 137-144; 
Sahni, M., Guenther, H.L., Fleisch, H., Bisphosphonates act on rat bone resorption through the mediation of osteoblasts (1993) J Clin Invest, 91 (5), pp. 2004-2011; 
Fleisch, H., Bisphosphonates: mechanisms of action (1998) Endocr Rev, 19 (1), pp. 80-100; 
Shinoda, H., Adamek, G., F{\'e}lix, R., Structure-activity relationships of various bisphosphonates (1983) Calcif Tissue Int, 35 (1), pp. 87-99; 
Pereira, J., Mancini, I., Walker, P., The role of bisphosphonates in malignant bone pain: a review (1998) J Palliat Care, 14 (2), pp. 25-36; 
Purohit, O.P., Radstone, C.R., Anthony, C., A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy (1995) Br J Cancer, 72 (5), pp. 1289-1293; 
Hillner, B.E., Ingle, J.N., Chlebowski, R.T., American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer (2003) J Clin Oncol, 21 (21), pp. 4042-4057. , [Erratum in J Clin Oncol 2004;22(7):1351]; 
Hillner, B.E., Ingle, J.N., Berenson, J.R., American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel (2000) J Clin Oncol, 18 (6), pp. 1378-1391; 
Lacerna, L., Hohneker, J., Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours (2003) Semin Oncol, 30 (5 SUPPL. 16), pp. 150-160; 
Lipton, A., Costa, L., Ali, S., Use of markers of bone turnover for monitoring bone metastases and the response to therapy (2001) Semin Oncol, 28 (4 SUPPL. 11), pp. 54-59; 
Brincker, H., Westin, J., Abildgaard, N., Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish Co-operative Study Group (1998) Br J Haematol, 101 (2), pp. 3280-3286; 
Berenson, J.R., Lichtenstein, A., Porter, L., Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group (1998) J Clin Oncol, 16 (7), pp. 593-602; 
Berenson, J.R., Vescio, R.A., Lee, S.R., Phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases (2001) Clin Cancer Res, 7 (3), pp. 478-485; 
Van Poznak, C.H., The use of bisphosphonates in patients with breast cancer (2002) Cancer Control, 9 (6), pp. 480-489; 
Marx, R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic (2003) J Oral Maxillofac Surg, 61 (9), pp. 1115-1117; 
Vannucchi, A.M., Ficarra, G., Antonioli, E., Osteonecrosis of the jaw associated with zoledronate therapy in patient with multiple myeloma (2005) Br J Haematol, 128 (6), pp. 738-739; 
Wang, J., Goodger, N.M., Pogrel, M.A., Osteonecrosis of the jaws associated with cancer chemotherapy (2003) J Oral Maxillofac Surg, 61 (9), pp. 1104-1107; 
Purcell, P.M., Boyd, I.W., Bisphosphonates and osteonecrosis of the jaw (2005) Med J Aust, 182 (8), pp. 417-418; 
Carter, G., Goss, A.N., Doecke, C., Bisphosphonates and avascular necrosis of the jaw: a possible association (2005) Med J Aust, 182 (8), pp. 413-415; 
Durie, B., Katz, M., Crowley, J., Osteonecrosis of the jaw and bisphosphonates (2005) N Engl J Med, 353, pp. 99-102; 
Migliorati, C.A., Bisphosphonates and oral cavity avascular bone necrosis (2003) J Clin Oncol, 21 (22), pp. 4253-4254; 
Robinson, N.A., Yeo, J.F., Bisphosphonates - a word of caution (2004) Ann Acad Med Singapore, 33 (4), pp. 48-49; 
Starck, W.J., Epker, B.N., Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report (1995) Int J Oral Maxillofac Implants, 10 (1), pp. 74-78; 
Melo, M., Obeid, G., Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy (2005) J Can Dent Assoc, 71 (2), pp. 111-113
},
	month = {2008///},
	pages = {99 - 106},
	abstract = {Purpose: Multiple myeloma, the second most common haematopoietic cancer, which represents the collection of plasma-cell neoplasms that invariably becomes fatal when self-renewing myeloma cells begin unrestrained proliferation. The major clinical manifestation of multiple myeloma is related to the loss of bone through osteolysis. This can lead to pathologic fractures, spinal cord compression, hypercalcaemia, and pain. It is also a major cause of morbidity and mortality in these patients, who frequently require radiation therapy, surgery and analgesic medications. Bisphosphonates are specific inhibitors of osteoclastic activity, and are currently used to prevent bone complications and to treat malignant hypercalcaemia in patients with multiple myeloma, or bone metastases from breast and prostate cancers. Hence, osteonecrosis of the mandible has been reported in three patients from Centro Hospitalar de Vila Nova de Gaia (CHVNG) with multiple myeloma treated for over 18-48 months with intravenous zoledronate, commonly prescribed for multiple myeloma therapy. Although, this report alerts clinicians about the potential complication of bone necrosis in patients receiving bisphosphonate therapy, many questions remain concerning the underlying pathogenesis of this process. Patients and methods: The medical and dental records of three patients with multiple myeloma, who were treated in CHVNG in the past 4 years, were reviewed. These three patients presented exposed bone and osteonecrosis of the mandible, and shared one common clinical feature: all of them were treated with bisphosphonate zoledronate, administered intravenously for long periods. Sequential orthopantomograms (OPGs) and histological evaluation have been analysed from the biopsies of the non healing dental extraction sites of these patients. Results: After a routine dental extraction, these patients developed avascular osteonecrosis of the mandible and secondary bone infection with Actinomyces israelii (actinomycotic osteomyelitis), with no evidence of metastatic disease evaluated by biopsy. In these three described clinical cases, surgical debridment without flap elevation, intensive antibiotherapy and the suspension of the zoledronate treatment allowed a partial recovery of the patients. The purpose of this clinical report is to point out that patients suffering from multiple myeloma can develop bone osteonecrosis induced by treatment with bisphosphonates. Research to determine the mechanism of this dental phenomenon is needed to fully validate and substantiate the possible link between bisphosphonate treatment of multiple myeloma or other cancer diseases and avascular osteonecrosis of the jaws. Until then, clinicians involved in the care of patients at risk should consider this possible complication. {\textcopyright} 2006 British Association of Plastic, Reconstructive and Aesthetic Surgeons.},
	keywords = {Actinomyces israelii, adult, aged, amoxicillin, antibiotic therapy, article, avascular necrosis, Avascular osteonecrosis, biopsy, Bisphosphonates, Bone Density Conservation Agents, case report, clinical feature, cyclophosphamide, cyclosporin, dexamethasone, Diphosphonates, drug induced disease, drug inhibition, drug withdrawal, erythropoietin, Female, histology, human, Humans, hypercalcemia, Imidazoles, Jaw, jaw avascular osteonecrosis, male, Mandibular Diseases, morbidity, mortality, Multiple myeloma, osteolysis, Osteonecrosis, pain, panoramic radiography, pathologic fracture, priority journal, Radiography, Panoramic, risk assessment, spinal cord compression, thalidomide, tooth extraction, zoledronic acid},
	isbn = {17486815 (ISSN)},
	url = {http://www.scopus.com/inward/record.url?eid=2-s2.0-36649035515\&partnerID=40\&md5=3cc23473fdb164be7f8e067bea9e436e},
	author = {Lobato, J.V. and Maur{\'\i}cio, A.C. and Rodrigues, J.M. and Cavaleiro, M.V. and Cortez, P.P. and Xavier, L. and Botelho, C. and Hussain, N.S. and Santos, J.D.}
}
